BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients

by Laroche-Clary, A, Chaire, V, Le Morvan, V, Neuville, A, Bertucci, F, Salas, S, Sanfilippo, R, Pourquier, P, Italiano, A
Published 2015

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group

by Cassier, P A, Lefranc, A, Y Amela, E, Chevreau, C, Bui, B N, Lecesne, A, Ray-Coquard, I, Chabaud, S, Penel, N, Berge, Y, Dômont, J, Italiano, A, Duffaud, F, Cadore, A-C, Polivka, V, Blay, J-Y
Published 2013

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours

by Adenis, A, Ray-Coquard, I, Italiano, A, Chauzit, E, Bui-Nguyen, B, Blay, J-Y, Tresch-Bruneel, E, Fournier, C, Clisant, S, Amela, E Y, Cassier, P A, Molimard, M, Penel, N
Published 2013

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)†

by Bompas, E., Le Cesne, A., Tresch-Bruneel, E., Lebellec, L., Laurence, V., Collard, O., Saada-Bouzid, E., Isambert, N., Blay, J. Y., Amela, E. Y., Salas, S., Chevreau, C., Bertucci, F., Italiano, A., Clisant, S., Penel, N.
Published 2015